Dublin, April 10, 2019 (GLOBE NEWSWIRE) -- The "Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application, End User - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
The global plasma fractionation market is projected to reach USD 34.94 billion by 2024 from USD 25.41 billion in 2019, at a CAGR of 6.6%.
Plasma fractionation is a process used to obtain various plasma-derived products for use in clinical specialties such as neurology, immunology, hematology, critical care, and pulmonology.
Market growth can be attributed to factors such as growing use of immunoglobulins in various therapeutic areas, rising geriatric population across the globe, the growing prevalence of respiratory diseases and AATD driving the uptake of alpha-1-antitrypsin, and increase in plasma collection. The indications for plasma products are also being expanded, which is expected to support market growth in the coming years. Another key trend in this market is the rising installation of fractionators in plasma collection centers.
In this report, the global plasma fractionation market is segmented by product, application, end user, and region.
Major players in the global plasma fractionation market include CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), BPL (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).
Geographic expansions and collaborations are the key strategies undertaken by these companies to maintain their positions in the market.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Plasma Fractionation Market Overview
4.2 Geographical Snapshot of the Plasma Fractionation Market
4.3 Plasma Fractionation Market: Regional Mix
4.4 Plasma Fractionation Market, Developing Countries vs Developed Countries
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Growing Use of Immunoglobulins in Various Therapeutic Areas
5.2.1.2 Rising Geriatric Population Across the Globe
5.2.1.3 Growing Prevalence of Respiratory Diseases and Aatd Driving the Uptake of Alpha-1-Antitrypsin
5.2.1.4 Increase in Plasma Collection
5.2.2 Market Restraints
5.2.2.1 High Cost and Limited Reimbursement
5.2.2.2 Emergence of Recombinant Alternatives
5.2.3 Market Opportunities
5.2.3.1 Rising Prevalence of Bleeding Disorders
5.2.4 Market Challenges
5.2.4.1 Stringent Government Regulations
6 Industry Insights
6.1 Introduction
6.2 Key Industry Trends
6.2.1 Focus on Increasing Fractionation Capacities
6.2.2 New Indications for Plasma Products
6.2.3 Rising Adoption of SCIg
6.2.4 Increasing Number of Fractionator-Owned Plasma Collection Centers
6.2.5 Growing Plasma Products Market in China
6.2.6 Increasing Focus of Plasma Fractionators Towards Manufacturing and Developing Recombinant Factors
6.3 Porter's Five Forces
6.4 Vendor Benchmarking
6.4.1 Product Portfolio Analysis: Plasma Fractionation Market
6.4.2 No. of Plasma Collection Centers and Fractionation Capacities, By Key Player
6.4.3 Business Presence of Key Players in the Value Chain
6.5 Pricing Analysis
7 Plasma Fractionation Market, By Product
7.1 Introduction
7.2 Immunoglobulins
7.2.1 Intravenous Immunoglobulins
7.2.1.1 IVIg Holds the Largest Share of the Immunoglobulins Market
7.2.2 Subcutaneous Immunoglobulins
7.2.2.1 Benefit of Self-Administration and Lower Incidence of Non-Serious Systemic Adverse Reactions Will Drive the Growth of the SCIg Market
7.2.3 Other Immunoglobulins
7.3 Coagulation Factor Concentrates
7.3.1 Factor VIII
7.3.1.1 Factor VIII Holds the Largest Share of the Coagulation Factor Concentrates Market
7.3.2 Factor IX
7.3.2.1 Growth in the Aging Population and the Rise in the Number of Hemophilic Patients is Expected to Drive the Growth in This Market
7.3.3 Von Willebrand Factor
7.3.3.1 Market Growth is Primarily Driven By the Increasing Prevalence and Diagnosis of Von Willebrand Disease and Hemophilia
7.3.4 Prothrombin Complex Concentrate
7.3.4.1 Advantages of Pcc Over Fresh Frozen Plasma Will Support Market Growth in This Segment
7.3.5 Fibrinogen Concentrates
7.3.5.1 Safety Profile, Accuracy, and Speed of Administration Have Supported the Growth of the Fibrinogen Concentrates Market
7.3.6 Factor XIII
7.3.6.1 Applications in Treating Rare Bleeding Disorders Will Contribute to the Demand for Factor XIII
7.4 Albumin
7.4.1 Wide Demand for Albumin as an Antioxidant and Volume Expander Will Driver Market Growth
7.5 Protease Inhibitors
7.5.1 Increasing Global Disease Burden Will Drive Demand for Protease Inhibitors
7.6 Other Products
8 Plasma Fractionation Market, By Application
8.1 Introduction
8.2 Neurology
8.2.1 Rising Prevalence of Major Age-Related Neurological Disorders to Drive This Market
8.3 Immunology
8.3.1 Increasing Prevalence of Immunodeficiency Disorders Among Children and Adults to Drive the Growth of This Market
8.4 Hematology
8.4.1 Growth in the Number of Hemophilia Patients to Drive the Demand for Coagulation Factor Concentrates and Immunoglobulins
8.5 Critical Care
8.5.1 Increasing Off-Label Use of Albumin and Rising Use of Anticoagulants to Drive the Demand for Plasma-Derived Critical Care Products
8.6 Pulmonology
8.6.1 Rising Prevalence of Alpha-1 Antitrypsin Deficiency and Copd to Drive the Plasma Fractionation Market for Pulmonology
8.7 Hemato-Oncology
8.7.1 Rising Number of Blood Cancer Patients to Drive the Demand for Plasma-Derived Products in Hemato-Oncology
8.8 Rheumatology
8.8.1 Increasing Prevalence of Rheumatic Conditions to Drive the Plasma Fractionation Market for Rheumatology
8.9 Other Applications
9 Plasma Fractionation Market, By End User
9.1 Introduction
9.2 Hospitals & Clinics
9.2.1 Improving Healthcare Infrastructure and Growth in the Number of Hospitals & ClinicsKey Factors Driving Growth
9.3 Clinical Research Laboratories
9.3.1 Increasing Number of Clinical Studies on New Therapeutic Indications for Plasma-Derived Products to Drive the Market for Clinical Research Laboratories
9.4 Academic Institutes
9.4.1 Increasing Basic Medical Research Activities and Growing Demand for New Drug Molecules to Drive the Demand for Plasma Products in Academic Institutes
10 Plasma Fractionation Market, By Region
11 Competitive Landscape
11.1 Overview
11.2 Market Share Analysis
11.2.1 Market Share Analysis, By Product,2018
11.2.1.1 Immunoglobulin Market, By Key Players
11.2.1.1.1 IVIg Market, By Key Players
11.2.1.2 Coagulation Factor Market, By Key Players
11.2.1.2.1 Factor VIII Market, By Key Players
11.2.1.3 Albumin Market, By Key Players
11.2.2 Market Share Analysis, By Region,2018
11.2.2.1 North America Plasma Fractionation Market, By Key Players
11.2.2.1.1 US Plasma Fractionation Market, By Key Players
11.2.2.2 Europe Plasma Fractionation Market, By Key Players
11.3 Competitive Leadership Mapping
11.3.1 Visionary Leaders
11.3.2 Innovators
11.3.3 Dynamic Differentiators
11.3.4 Emerging Companies
11.4 Competitive Scenario and Trends
11.4.1 Product Launches/Approvals
11.4.2 Expansions
11.4.3 Acquisitions
11.4.4 Agreements, Collaborations, Joint Ventures, and Partnerships
12 Company Profiles
- Bio Products Laboratory (BPL)
- Biotest
- China Biologic Products
- CSL
- GC Pharma (Green Cross Corporation)
- Grifols
- Japan Blood Products Organization
- Kedrion
- LFB
- Octapharma
- Sanquin
- Shanghai RAAS Blood Products
- Shire
For more information about this report visit https://www.researchandmarkets.com/research/2jkvvz/plasma?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.